Robert L. Fine, MD, from Columbia University, comments on the utility of CAPTEM in chemotherapy-resistant neuroendocrine tumors.
Robert L. Fine, MD
Articles by Robert L. Fine, MD
Robert L. Fine, MD, from Columbia University, discusses reducing the risk of relapse in patients with pancreatic cancer.
Latest Updated Articles
The Utility of CAPTEM in Chemo-Resistant Neuroendocrine TumorsPublished: April 24th 2014 | Updated:
Reducing the Risk of Relapse in Patients With Pancreatic CancerPublished: February 24th 2014 | Updated: